SEC Form 4 · accession 0001209191-17-022342
Adamas Pharmaceuticals Inc · ADMS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Gregory T Went
Officer — Chief Executive Officer · Director
Period of report
Mar 21, 2017
Accepted (ET)
Mar 22, 2017 · 5:06 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001328143
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Mar 21, 2017 | S | 2,807 | $17.03 | D | 166,526 | D | |
| Common Stock | holding | — | — | — | 195,392 | I | By Trust | |
| Common Stock | holding | — | — | — | 80,000 | I | Gregory T. Went & Marjorie S. Went ttees 2012 Irr Trust FBO Bridget Elise Went | |
| Common Stock | holding | — | — | — | 80,000 | I | Gregory T. Went & Marjorie S. Went ttees 2012 Irr Trust FBO Cora Margaret Went |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Pursuant to the mandatory sale to cover withholding tax requirements of the issuer's equity incentive plan, the shares were sold to cover the tax obligation realized upon the vesting of restricted stock units.
- F2The shares were sold at prices ranging from $16.96 to 17.215. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.